Switching GLP-1 medications: what the interaction claims get wrong

What's this video probably claiming?

Based on the caption and hashtag context, this video is almost certainly walking viewers through what happens when you switch between GLP-1 receptor agonists, whether that's moving from liraglutide (Victoza/Saxenda) to semaglutide (Ozempic/Wegovy), or from semaglutide to tirzepatide (Mounjaro/Zepbound). The creator appears to be addressing a follower question, which usually means the content covers transition timelines, washout periods, and whether medications can overlap or stack. These are legitimate clinical questions. The problem is that switching protocols are genuinely complex, differ by drug half-life and indication, and are not well-standardized across prescribers. A TikTok format, however well-intentioned, flattens that complexity into something that sounds more certain than the evidence actually supports. Viewer counts near 17K mean a lot of people are making decisions based on whatever framework this creator is presenting.

What does the science actually show?

The pharmacokinetics here matter more than most creators acknowledge. Semaglutide has a half-life of approximately 165 to 184 hours, meaning it takes roughly five weeks to clear from the body after the last dose. Liraglutide, by contrast, clears in about 13 hours. Tirzepatide's half-life sits around five days. These differences are not trivial. A 2022 analysis in Diabetes, Obesity and Metabolism (Knudsen and Lau) outlined that overlapping GLP-1 agents theoretically compounds receptor agonism without proportionally increasing efficacy, while gastrointestinal adverse events, nausea, vomiting, delayed gastric emptying, do compound. There is no published randomized controlled trial specifically studying the clinical outcomes of direct GLP-1 to GLP-1 switching in humans. The SUSTAIN and SURPASS trial programs studied their respective drugs in isolation or against placebo and metformin, not against each other in transition protocols. Prescribers are largely working from pharmacokinetic inference, not head-to-head switching data.

Where does the social media noise diverge from clinical reality?

The biggest gap between what circulates online and what clinicians actually deal with is the framing of switching as a clean, rule-based process. You'll see claims like "wait two weeks" or "start at the lowest dose of the new drug regardless" presented as settled protocol. Neither of those is backed by a specific regulatory guideline from the FDA or EMA. The American Diabetes Association's 2024 Standards of Care mention transitioning between agents in the context of cardiovascular benefit and tolerability, but do not provide a switching algorithm. What's also routinely missing from these videos is the drug interaction dimension beyond the GLP-1 class itself. Both semaglutide and tirzepatide slow gastric emptying, which affects oral medication absorption, including oral contraceptives, levothyroxine, and certain antihypertensives. A 2023 study in Clinical Pharmacokinetics (Hausner et al.) confirmed gastric emptying delay with oral semaglutide specifically affects co-administered drug Cmax. That's a real interaction most switching content ignores entirely.

What should you actually know?

If you are switching GLP-1 medications, a few things are reasonably well-supported. Starting the new agent at the lowest available dose is a conservative, sensible approach given cumulative GI burden, though this is expert consensus, not trial data. Because semaglutide has a long half-life, some clinicians allow overlap or immediate transition without a washout, but this is a prescriber-level judgment call, not a blanket recommendation. Tirzepatide acts on both GIP and GLP-1 receptors, making it pharmacologically distinct from pure GLP-1 agonists. Do not assume dose equivalency between agents. There is no validated conversion chart. A dose that produced tolerable effects on one drug does not translate predictably to another. Anyone managing type 2 diabetes who switches should have glucose monitoring adjusted accordingly, because efficacy timelines differ. And critically, if you are on any oral medications with narrow therapeutic windows, flag the switch to whoever prescribes those drugs too, not just your GLP-1 prescriber.